Natura &Co significantly outperforms global CFT market in Q3 with strong sales growth and margin improvement

Recent highlights include strengthened capital structure, launch of &Co Pay financial services platform and certification of Aesop as a B Corp™

PR Newswire

SÃO PAULO, Nov. 12, 2020 /PRNewswire/ — Natura &Co (NYSE – NTCO; B3 – NTCO3) posted a strong growth in revenue in the third quarter, significantly outperforming the global Cosmetics, Fragrance, and Toiletries market, as the sustained ramp-up in digital sales across all brands continued. Consolidated sales stood at R$10.4 billion, up 31.7% in Brazilian Reais and 11.6% at constant currency.

The Group also strengthened its capital structure with the successful completion in October of a US$1 billion capital raise. The transaction allows for balance sheet optimization by accelerating deleveraging while also enabling investments to drive growth in strategic priorities including Avon’s integration, Group digitalization, geographic expansion, and the Group’s 2030 Sustainability commitments.

A key sustainability milestone included Aesop’s certification as a B CorpTM; joining Natura, The Body Shop, and a movement of businesses dedicated to achieving the highest social, economic, and environmental standards.

Natura &Co also took another step forward in its continued digitalization with the launch of &Co Pay, its proprietary financial services platform. &Co Pay will help drive productivity to consultants and representatives by allowing them access to key financial services, promoting digital and financial inclusion. Launching first in Latin America, &Co Pay will be rolled out globally within the next couple of years.

Roberto Marques, Executive Chairman and Group CEO of Natura &Co, declared: “Enabled by continued digitalization, our brands delivered strong results in the third quarter, with significant growth in sales and margin improvement. In an environment that has remained challenging throughout the world as a result of the Covid-19 pandemic, we delivered superior results compared to the CFT market both globally and in Brazil. Our performance this quarter attests to the strength of our fundamentals, our unparalleled Direct-to-Consumer reach, and the resilience of our omnichannel, multi-brand model.”

Natura &Co’s consolidated net revenue growth was driven by outperformance by both Natura and Aesop, solid growth by The Body Shop, and growth in sales in Reais by Avon. Adjusted EBITDA was R$1,547.3 million, with margin of 14.8%, a gain of 330 basis points, driven by revenue growth, improved gross margin, and cost discipline across all businesses.

Even as many retail markets reopened, the Group experienced continued strong acceleration in digital social selling and e-commerce, with total e-commerce sales growing more than 115% in the quarter vs. the same period last year. At Natura and Avon combined, e-commerce sales grew more than 80% through consultants sharing their online stores. Online sales at Aesop were up 264%, and e-commerce sales at The Body Shop grew 103%. Digital social selling also progressed. At Avon globally, sales via representatives sharing e-brochures more than doubled, and the number of consumers accessing Avon’s e-brochure increased nearly 70% vs. Q3-19. At Natura, content sharing grew by more than 170% since the first quarter of this year, and the number of orders increased 45% vs. Q3-19 through the more than 1 million consultant online stores (+75% vs. Q3-19).

Natura &Co Latam’s net revenue increased by 29.5% in BRL. The Natura brand’s net revenue rose by a very strong 41.2% in BRL, supported by both Brazil (+30.5%), outperforming the domestic CFT market, and Hispanic Latam (+65.7%). The Avon brand’s net revenue increased by 19.3% in BRL (+9.9% at CC). Excluding the cyber incident effect that shifted R$390 million in sales to Q3, Avon sales were up 3.3%, including +6.1% in Brazil, its first growth in the country since Q4-18, thanks to increased representative numbers and higher activity. Adjusted EBITDA for Natura &Co Latam was R$1,002.8 million, up 96.1%, and adjusted EBITDA margin was 16.5% (+560 bps).

Avon International, which comprises Avon’s activities in 50 markets throughout Europe, Asia, Africa, and the Middle East, saw its Q3 net revenue grow by 22.5% in BRL as most markets showed signs of recovery. Excluding the positive phasing effect of R$60 million from the cyber incident, growth was 19.5%. Avon’s new brand campaign, Watch Me Now, premiered in September across more than 30 countries. Adjusted EBITDA was R$183 million, with 7.4% margin (-200 bps).

The Body Shop’s net revenue increased 51.9% in BRL, driven by a very strong performance in online and direct sales. Consumers continued to shift to e-commerce and At-Home (direct sales), with growth of more than 103% and 333%, respectively, significantly offsetting slower recovery of retail sales. At the end of the quarter, 97% of stores were reopened. Adjusted EBITDA in Q3 was R$308.3 million, with adjusted margin of 22.3% (+360 bps).

Aesop continued its success story from Q2, with strong double-digit growth in both sales and profitability in Reais. Net sales grew 67.2% in Q3 as a 264% increase in digital sales helped offset ongoing partial retail closures related to Covid-19 in major markets such as the US and Australia. 95% of the retail network had reopened at the end of the quarter. EBITDA in Q3 grew by 121.6% to R$154.4 million, with margin up 770 basis points to 31.3%. Aesop’s commitment to sustainable business practices was underscored by its certification as a B CorpTM on November 9.

About Natura &Co

Natura &Co is a global, purpose-driven, multi-channel and multi-brand cosmetics group which includes Avon, Natura, The Body Shop and Aesop. Natura &Co posted net revenues of R$ 14.4 billion in 2019 and R$32.9 billion on a proforma basis, including Avon. The four companies that form the group are committed to generating positive economic, social and environmental impact. For 130 years Avon has stood for women: providing innovative, quality beauty products which are primarily sold to women, through women. Founded in 1969, Natura is a Brazilian multinational in the cosmetics and personal care segment, leader in direct sales. Founded in 1976 in Brighton, England, by Anita Roddick, The Body Shop is a global beauty brand that seeks to make a positive difference in the world. The Australian beauty brand Aesop was established in 1987 with a quest to create a range of superlative products for skin, hair and the body.

Press Contact

Brunswick Group
NATURA&[email protected]

Tristan Bourassin: +1 (917) 200 8667

Cision View original content:http://www.prnewswire.com/news-releases/natura-co-significantly-outperforms-global-cft-market-in-q3-with-strong-sales-growth-and-margin-improvement-301172432.html

SOURCE Natura &Co

WeissLaw LLP Reminds ALAC, ALSK, TNAV, and EIGI Shareholders About Its Ongoing Investigations

PR Newswire

NEW YORK, Nov. 12, 2020 /PRNewswire/ —


If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:


Joshua Rubin, Esq.

WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

Alberton Acquisition Corporation (NASDAQ: ALAC)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alberton Acquisition Corporation (NASDAQ: ALAC) in connection with the company’s proposed merger with SolarMax Technology, Inc. (“SolarMax”).  Under the terms of the merger agreement, ALAC will acquire SolarMax through a reverse merger, with SolarMax continuing as a publicly-traded company.  If you own ALAC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:  http://www.weisslawllp.com/ALAC/ 

Alaska Communications Systems Group, Inc. (NASDAQ: ALSK)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alaska Communications Systems Group, Inc. (NASDAQ: ALSK) in connection with the proposed acquisition of the company by a consortium composed of Macquarie Capital and GCM Grosvenor pursuant to which, ALSK shareholders will receive $3.00 per share in cash for each share of ALSK common stock that they hold.  If you own ALSK shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:  https://www.weisslawllp.com/ALSK/ 

Telenav, Inc. (NASDAQ: TNAV)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Telenav, Inc. (NASDAQ: TNAV) in connection with the proposed interested-party acquisition of the company by V99, Inc., a corporation led by TNAV’s President and CEO HP Jin.  Under the terms of the acquisition agreement, TNAV shareholders will receive $4.80 per share in cash for each share of TNAV that they hold.  If you own TNAV shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/TNAV/ 

Endurance International Group Holdings, Inc. (NASDAQ: EIGI)  

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Endurance International Group Holdings, Inc. (NASDAQ: EIGI) in connection with the proposed acquisition of the company by affiliates of Clearlake Capital Group, L.P.  Under the terms of the acquisition agreement, EIGI shareholders will receive $9.50 per share in cash for each share of EIGI that they hold.  If you own EIGI shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/EIGI/

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/weisslaw-llp-reminds-alac-alsk-tnav-and-eigi-shareholders-about-its-ongoing-investigations-301172398.html

SOURCE WeissLaw LLP

SHAREHOLDER ALERT: WeissLaw LLP Investigates Cancer Genetics, Inc.

PR Newswire

NEW YORK, Nov. 12, 2020 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cancer Genetics, Inc. (“CGIX” or the “Company”) (NASDAQ: CGIX) in connection with the Company’s proposed merger with privately-held StemoniX, Inc. (“StemoniX”). Under the terms of the merger agreement, CGIX will acquire all of the outstanding capital stock of StemoniX in exchange for a number of shares of CGIX representing approximately 78% of CGIX’s outstanding common stock.  The combined company will continue to trade on the NASDAQ, with StemoniX becoming a wholly-owned subsidiary of CGIX.  Upon closing of the proposed merger, CGIX’s current stockholders will own just 22% of the combined company.


If you own CGIX shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:


http://www.weisslawllp.com/CGIX/


Or please contact:



Joshua Rubin, Esq.

WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

WeissLaw is investigating whether CGIX’s board acted in the best interest of CGIX’s public stockholders in agreeing to the proposed transaction, whether the deal’s equity split is fair to CGIX stockholders, and whether all information regarding the sales process undertaken by the board and financial analyses supporting the transaction is fully and fairly disclosed to CGIX’s public stockholders. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-cancer-genetics-inc-301172397.html

SOURCE WeissLaw LLP

SHAREHOLDER ALERT: WeissLaw LLP Investigates Jaws Acquisition Corp.

PR Newswire

NEW YORK, Nov. 12, 2020 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Jaws Acquisition Corp. (“JWS” or the “Company”) (NYSE: JWS) in connection with the Company’s proposed merger with privately-held healthcare provider Cano Health, LLC (“Cano”).  Under the terms of the merger agreement, JWS will acquire Cano through a reverse merger that will result in Cano becoming a public company traded on the New York Stock Exchange under the new ticker symbol “CANO.”  The transaction is expected to have an enterprise value of approximately $4.4 billion on a pro forma basis.


If you own JWS shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:


https://www.weisslawllp.com/JWS/


Or please contact:

Joshua Rubin, Esq.


WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771

[email protected]

WeissLaw is investigating whether JWS’s board acted in the best interest of JWS’s public stockholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of Cano, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to JWS’s public stockholders. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-jaws-acquisition-corp-301172389.html

SOURCE WeissLaw LLP

Meritor and DTNA Extend Agreement to Provide Air Disc Brakes for Freightliner Cascadia® Trucks

Long-term Agreement for Air Disc Brakes Runs Through 2025

PR Newswire

TROY, Mich., Nov. 12, 2020 /PRNewswire/ — Meritor, Inc. (NYSE: MTOR) and Daimler Trucks North America (DTNA) today announced that Meritor® EX+™ LS air disc brakes (ADB) will be standard on all-wheel positions on Freightliner Cascadia® truck models through 2025. The award is part of a broader five-year extension of the current agreement with DTNA that includes Meritor’s axles, drivelines, drum brakes, industrial and aftermarket products for the North America market through 2027.

“DTNA’s decision to provide EX+ LS air disc brakes on its Freightliner Cascadia is a reflection of how well our brakes have performed and the positive feedback from its customers,” said Saad Malik, general manager for Meritor Front Drivetrain. “We’re proud to continue our partnership with a leading manufacturer of heavy-duty trucks in North America.”

“Meritor air disc brakes have been standard on Freightliner Cascadia trucks since 2018, complementing the best truck with the best components,” said Pete Hobbs, vice president of On-Highway Market Development for DTNA. “Meritor EX+ air disc brakes have exceeded our high expectations and, more importantly, the expectations of our customers. We are pleased to include Meritor’s latest ADB offering to our customers, and we are confident that the EX+ LS air disc brake will continue to impress our on-highway customers with the performance, safety and weight reduction they deliver.”

Per the new contract, the EX+ LS air disc brakes will be added to the Freightliner Cascadia with build dates beginning in the first quarter of 2021. Other Freightliner and Western Star trucks in the DTNA portfolio will also offer EX+ LS air disc brakes as an option.

The EX+ LS, Meritor’s lightest air disc brake, is designed specifically for linehaul and trailer applications in the North American market. Other features include:

  • Single-piston design validated to the same taper wear criteria as Meritor’s EX+™ L twin-piston brake
  • Enhanced piston seal to provide exceptional protection from heat exposure and debris
  • Adjuster mechanism offers reliable and consistent brake performance
  • MA9300 N-level proprietary friction with 2025 reduced copper compliance

Fleets with EX+ LS air disc brakes on their trucks and trailers benefit from commonality of parts because they can stock fewer parts, and replacement can be simplified by ordering through Meritor Aftermarket.

About Meritor
Meritor, Inc. is a leading global supplier of drivetrain, mobility, braking and aftermarket solutions for commercial vehicle and industrial markets. With more than a 110-year legacy of providing innovative products that offer superior performance, efficiency and reliability, the company serves commercial truck, trailer, off-highway, defense, specialty and aftermarket customers around the world. Meritor is based in Troy, Mich., United States, and is made up of more than 7,000 diverse employees who apply their knowledge and skills in manufacturing facilities, engineering centers, joint ventures, distribution centers and global offices in 19 countries. Meritor common stock is traded on the New York Stock Exchange under the ticker symbol MTOR. For important information, visit the company’s website at www.meritor.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/meritor-and-dtna-extend-agreement-to-provide-air-disc-brakes-for-freightliner-cascadia-trucks-301172431.html

SOURCE Meritor, Inc.

PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020

SPARTA, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”™), announced today that the Company has rescheduled its 2020 third quarter financial results call to Monday, November 16, 2020.

Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

Date Monday, November 16, 2020
Time 4:30 p.m. ET
Toll free (U.S.) (866) 394-2901
International
Conference ID
(616) 548-5567
2219797
Webcast (live and replay) www.plxpharma.com under the ‘Investor Relations’ section.

A replay of the conference call will be available for two weeks after the call’s completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International). The conference ID for the replay is 2219797. The archived webcast will be available for 30 days via the aforementioned URL.

About VAZALORE

VAZALORE 325 mg is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy with faster, reliable and more predictable platelet inhibition as compared to enteric-coated aspirin, while also reducing the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. PLx is focused on collecting the data, including results from a bioequivalence study, required for post-approval manufacturing changes, which will be included in the sNDA filing for VAZALORE 325 mg and to support approval of low dose VAZALORE 81 mg.

About PLx Pharma Inc.

PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products. The PLxGuard delivery system works by targeting delivery of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with aspirin and ibuprofen, and potentially other drugs.

To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

Contact

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: [email protected]

Shake® : The Creator Marketplace® – Opens for Business

Orlando, Florida, Nov. 12, 2020 (GLOBE NEWSWIRE) — IZEA Worldwide, Inc. (NASDAQ: IZEA), the premier provider of influencer marketing technology, data, and services for the world’s leading brands, today announced that transactions have been enabled for all registered Shake users. Buyers are now able to purchase digital services from sellers who are social media influencers, photographers, writers, musicians, and more. Creators are able to list available “Shakes” on their accounts in the platform and transact with interested buyers.

“We are thrilled to open the Shake marketplace for all buyers and sellers,” commented IZEA Founder, Chairman, and CEO Ted Murphy. “The launch of this platform underscores our commitment to developing technology that generates more opportunities for creators to collaborate with buyers and earn a living developing digital content. Shake will dramatically expand our buyer universe beyond the enterprise customers we serve today, opening the door for brands and agencies of all types and sizes to become part of the IZEA ecosystem. This is day one for Shake and the beginning of a much broader transformation for our company that will continue to unfold over the coming years.”

The Shake platform is aimed at digital creatives seeking freelance “gig” work. According to the Bureau of Labor Statistics, there are 1.6 million “gig economy” workers in the United States alone. Business Insider Intelligence data from December 2019 predicts that the influencer marketing industry as a whole is projected to reach $15 billion by 2022.

Key Information About Shake:

Creators First™ Pricing

IZEA’s standard transaction fee is 15% of the sale price, while competitor Fiverr has a combined take rate of 27% between buyer and seller fees. A minimal floor of $50 per listing vs. $5 on competing platforms is designed to ensure fair compensation for creators. The current average listing price is $1,642.

Curated Listings and Categories

Shake is focused on high quality digital services that are commonly offered by advertising agencies, media companies, and talent agencies. Listings are reviewed and curated in an effort to provide buyers with the best possible experience.

Individual and Commercial Content Licenses

Digital services can be offered as either personal or full commercial licenses, allowing creators to sell personalized video messages or even video conferences directly to their fan base.

Public Marketplace

In comparison to IZEA’s current platform which offers large enterprise customers access to IZEA’s private network of influencers and content creators, Shake is public. There is no subscription needed to see the creators who are interested in working directly with buyers.

Universal Accounts and Finances

IZEAx and Shake share a common user authentication service and financial backend, among other IZEAx technologies. Enterprise IZEAx customers can make purchases through Shake with their existing accounts and funds. Creators will also be able to use their funds earned in either IZEAx or Shake to hire other creators in the platform.

IZEA kicked off its broadest marketing effort ever today, starting with a social media influencer campaign powered by IZEA’s influencer marketing platform, IZEAx Unity Suite. Shake will also be promoted through a variety of paid media channels including Facebook, Instagram, TikTok, search, and display. Ads will feature select Shake listings and directly promote opportunities to collaborate with Shake creators.

Influencer Marketing Diversity Mandate

In tandem with the launch of the Shake campaign, IZEA has mandated that no less than 40% of the influencer sponsorships and paid promotions of Shakes are allocated to further promote diversity efforts by allocating marketing spend to non-white creators and those who are members of the LGBTQ community.

To become a buyer or seller in Shake visit shake.izea.com

About IZEA Worldwide, Inc.

IZEA Worldwide, Inc. (“IZEA”) is a marketing technology company providing software and professional services that enable brands to collaborate and transact with the full spectrum of today’s top social influencers and content creators. The company serves as a champion for the growing Creator Economy, enabling individuals to monetize their content, creativity, and influence. IZEA launched the industry’s first-ever influencer marketing platform in 2006 and has since facilitated nearly 4 million transactions between online buyers and sellers. Leading brands and agencies partner with IZEA to increase digital engagement, diversify brand voice, scale content production, and drive measurable return on investment.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking  terms such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” or other comparable terms. Examples of forward-looking statements include, among others, statements we make regarding expectations of sales activity, revenue and margins based on bookings, plans to increase the size of our sales team, the financial impact of investments in our software business, and continuation of new IZEAx customers and their effect on future sales.

Forward-looking statements involve inherent risks and uncertainties, which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors, including, among others, the following: competitive conditions in the content and social sponsorship segment in which IZEA operates; failure to popularize one or more of the marketplace platforms of IZEA; changing economic conditions that are less favorable than expected; and other risks and uncertainties described in IZEA’s periodic reports filed with the Securities and Exchange Commission.  IZEA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

Martin Smith
IZEA Worldwide, Inc.
Phone: 407-674-6911
Email: [email protected]

CenterPoint Energy, Inc. to Host Webcast of Fourth Quarter & Full Year 2020 Earnings Conference Call

Houston, TX, Nov. 12, 2020 (GLOBE NEWSWIRE) —  

Date:  February 25, 2021

Time:  7:00 a.m. Central time or 8:00 a.m. Eastern time

Listen via internet:  http://investors.centerpointenergy.com/

Click “Investors”, and click the link “CenterPoint Energy, Inc. Fourth Quarter & Full Year 2020 Earnings Conference call Webcast”

As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more than 7 million metered customers in Arkansas, Indiana, Louisiana, Minnesota, Mississippi, Ohio, Oklahoma and Texas. As of September 30, 2020, the company owned approximately $33 billion in assets and also owned 53.7 percent of the common units representing limited partner interests in Enable Midstream Partners, LP, a publicly traded master limited partnership that owns, operates and develops strategically located natural gas and crude oil infrastructure assets. With approximately 9,600 employees, CenterPoint Energy and its predecessor companies have been in business for more than 150 years. For more information, visit CenterPointEnergy.com.

Brandi Summersill - (713) 207-6500

Prairie Provident Resources Announces Third Quarter 2020 Financial and Operating Results

CALGARY, Alberta, Nov. 12, 2020 (GLOBE NEWSWIRE) — Prairie Provident Resources Inc. (“Prairie Provident”, “PPR” or the “Company”) today announces our financial and operating results for the three and nine months ended September 30, 2020. PPR’s unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2020 (“Interim Financial Statements”) and related Management’s Discussion and Analysis (“MD&A”) for the three and nine months ended September 30, 2020 are available on our website at www.ppr.ca and filed on SEDAR.

PPR’s third quarter financial results continue to reflect the significant decline in global energy demand and resultant impact on crude oil pricing caused by the COVID-19 pandemic since early 2020. While the health and safety of our employees, partners and communities remains a priority, the Company has proactively taken steps to maintain our liquidity and financial position during this unprecedented time.

Initiatives undertaken include suspending the capital program; identifying immediate and targeted operating cost reductions; reducing compensation across the organization; and reaching an agreement with our lenders to defer the Company’s borrowing base re-determination and to suspend cash interest payments on our 15% subordinated unsecured notes due October 31, 2021 (“Senior Notes”).

As a result of these initiatives, the Company expects to realize adjusted funds flow (“AFF”)1 savings of approximately $8.0 million to $10.0 million for 2020. In addition, PPR has WTI hedges on over 80% of our 2020 and 30% of our 2021 forecast base oil production (net of royalties), respectively, which protect our operating cash flows and provide further resiliency amid continued volatility.  At September 30, 2020, our hedges were fair valued at over $4.7 million. 

Q3 2020 HIGHLIGHTS

  • Due to the ongoing adverse effects of the COVID-19 pandemic and OPEC+ supply issues, oil prices were significantly depressed throughout the second quarter of 2020, and despite moderate improvement in the third quarter of 2020 remain significantly lower year-over-year from 2019 levels. PPR’s Q3 2020 cash flows were partially protected by our hedging program, which brought in $2.8 million of realized gains for the quarter.
  • Production averaged 4,516 boe/d (68% liquids) in the third quarter of 2020, a 27% or 1,698 boe/d decrease from the same period in 2019, primarily driven by natural declines and production shut-ins, partially offset by production from our 2019/2020 drilling program. In response to weak oil prices, PPR permanently shut-in approximately 130 boe/d of uneconomic oil production and suspended our capital program during the second quarter of 2020, and also deferred workover activities to preserve reserves value and liquidity, which resulted in temporary production loss over the quarter. As oil prices have partially recovered, PPR resumed workover activities in the third quarter of 2020 on select projects that meet our current economic thresholds of less than one-year payout.
  • In addition to shutting in uneconomic production, PPR implemented various other cost reduction initiatives including the realignment of field structure, negotiating rate reductions with vendors and suspending workover activities.  These cost savings initiatives together with lower production, resulted in a decrease in operating expenses of $1.1 million compared to the third quarter of 2019, partially offset by a higher level of workover activities. 
  • Operating netback1 after the impact of realized gains on derivatives was $6.3 million ($15.15/boe) for the third quarter of 2020, reflecting a decrease of $4.5 million or 42% from the same period in 2019. Our hedging program provided $2.8 million of realized gains in the third quarter of 2020 which partially mitigated a 29% drop in realized oil prices from the corresponding period in 2019. 
  • Net capital expenditures1 during the second quarter of 2020 were nominal, as a result of the suspension of the capital program.
  • Adjusted funds flow1, excluding $0.1 million of decommissioning settlements, was $3.9 million ($0.02 per basic and diluted share) for the third quarter of 2020, a 40% or $2.7 million decrease from the same quarter in 2019. Primary contributors to the decrease were lower production volumes and lower realized oil prices, which were partially offset by a reduction in operating expenses, royalties, general and administrative (“G&A”) expenses and cash interest expenses.
  • Net loss totaled $8.3 million in the third quarter of 2020 compared to a net loss of $2.3 million in the same period of 2019, driven primarily by a non-cash unrealized loss on derivative instruments of $3.9 million in the third quarter of 2020 versus an unrealized gain of $5.2 million in the third quarter of 2019. The unrealized loss on derivative instruments was due to a decrease in derivative asset value between June 30, 2020 and September 30, 2020.  The decrease in derivative asset value during the third quarter of 2020 was largely due to realizing $2.8 million of gains from contracts settled in the period.
  • Net debt1 at September 30, 2020 totaled $117.6 million, up $6.2 million from December 31, 2019. The increase is attributed to an unrealized foreign exchange loss of $2.0 million, which was driven by a weaker Canadian dollar relative to the US dollar on the Company’s US-dollar denominated debt, amortization of deferred financing costs and an increase of $5.3 million in deferred interest on the Company’s bank debt, partially offset by a year-to-date AFF1 that exceeds capital expenditures, finance lease payments and decommissioning settlements.
  • A lender redetermination of the senior secured revolving note facility (“Revolving Facility”) borrowing base, originally scheduled for the spring of 2020, continues to be temporarily deferred. Until the redetermination is concluded, the Company agreed to direct excess funds, after payment of all operating, G&A and other costs of conducting our business, to the repayment of borrowings on the Revolving Facility and to not make further advances under that facility. PPR also agreed to a 200 basis point payment-in-kind margin increase on outstanding advances, payable on maturity of the Revolving Facility. 
  • The maturity date of the Revolving Facility is April 30, 2021. As the maturity date is within 12 months from September 30, 2020, the total outstanding amount under the Revolving Facility is classified under current liabilities as at September 30, 2020. The Company and our lenders continue to work towards a long‐term solution on the credit facilities.  The lenders under both the Revolving Facility and the Senior Notes agreed to waive the application of all financial covenants for September 30, 2020.  
  • At September 30, 2020, PPR had US$57.3 million of borrowings drawn against the US$60.0 million Revolving Facility, comprised of US$30.3 million (C$40.5 million equivalent using the exchange rate at the time of borrowing, plus C$0.4 million equivalent of deferred interest, using the September 30, 2020 exchange rate of $1.00 USD to $1.33 CAD) of CAD-denominated borrowing and US$27.0 million of USD-denominated borrowing (C$35.7 million, plus C$0.4 million of deferred interest equivalent using the September 30, 2020 exchange rate). In addition, US$34.4 million (C$38.0 million, plus C$7.8 million of deferred interest  equivalent using the September 30, 2020 exchange rate) of Senior Notes were outstanding at September 30, 2020, for total borrowings of US$91.7 million (C$122.9 million using the September 30, 2020 exchange rate).

1  Non-IFRS measure – see below under “Non-IFRS Measures”

CEO SUCCESSION

Prairie Provident also announces that Tim Granger, Chief Executive Officer and a director of the Company, has decided to retire after almost eight years of service to PPR and its predecessor, Lone Pine Resources, and that Tony van Winkoop will be appointed Chief Executive Officer.

“The board of directors, shareholders and employees of Prairie Provident wish to thank Tim for his years of loyal service, sound leadership and stewardship.  We wish him well in his future endeavors,” said Patrick McDonald, Chair of the Board of Directors. “On behalf of the Board, I would also like to congratulate Tony on his appointment as CEO, a well-deserved recognition of his contribution to the Company and moreover demonstration of our confidence in his abilities to lead the Company,” said McDonald.

Mr. van Winkoop, who has served as Vice President, Exploration for over 5 years and now President, was Chief Executive Officer of Arsenal Energy until its combination with Lone Pine Resources to form Prairie Provident in September 2016, and has been an integral member of the executive leadership team ever since.

The changes will be effective at the annual meeting of PPR shareholders to be held on December 18, 2020, at which Mr. van Winkoop will also stand for election to the board of directors together with Patrick McDonald (Chairman), Derek Petrie, William Roach, Ajay Sabherwal and Rob Wonnacott.  Mr. Granger and Terence (Tad) Flynn are not standing for re-election.

A notice of meeting and information circular for the 2020 shareholders’ meeting has been filed on SEDAR under the Company’s issuer profile at www.sedar.com, and will be disseminated to shareholders in the coming days.

FINANCIAL AND OPERATING SUMMARY

  Three Months Ended

September 30,
Nine Months Ended

September 30,
($000s except per unit amounts) 2020   2019   2020   2019  
Production Volumes        
Crude oil (bbls/d) 2,931   4,029   3,188   4,051  
Natural gas (Mcf/d) 8,704   12,092   9,411   11,792  
Natural gas liquids (bbls/d) 135   169   134   172  
Total (boe/d) 4,516   6,214   4,891   6,188  
% Liquids 68 % 68 % 68 % 68 %
Average Realized Prices        
Crude oil ($/bbl) 43.70   61.83   35.81   61.81  
Natural gas ($/Mcf) 2.26   1.14   2.09   1.57  
Natural gas liquids ($/bbl) 24.96   25.53   22.47   30.26  
Total ($/boe) 33.47   43.01   27.99   44.29  
Operating Netback ($/boe)1        
Realized price 33.47   43.01   27.99   44.29  
Royalties (3.38 ) (4.85 ) (2.78 ) (4.57 )
Operating costs (21.79 ) (18.92 ) (20.80 ) (20.86 )
Operating netback 8.30   19.24   4.41   18.86  
Realized gains (losses) on derivatives 6.85   (0.29 ) 9.65   (1.02 )
Operating netback, after realized gains (losses) on
derivatives
15.15   18.95   14.06   17.84  
  1. Operating netback is a Non-IFRS measure (see “Non-IFRS Measures” below).
Capital Structure

($000s)
September 30, 2020   December 31, 2019  
Working capital1 3.4   2.2  
Bank debt2 (121.0 ) (113.6 )
Total net debt3 (117.6 ) (111.4 )
Common shares outstanding (in millions) 172.1   171.4  
  1. Working capital (deficit) is a Non-IFRS measure (see “Non-IFRS Measures” below) calculated as current assets less current portion of derivative instruments, minus accounts payable and accrued liabilities.
  2. Bank debt includes the Revolving Facility and the Senior Notes.
  3. Net debt is a Non-IFRS measure (see “Non-IFRS Measures” below), calculated by adding working capital (deficit) and bank debt.
  Three Months Ended

September 30,
Nine Months Ended

September 30,
Drilling Activity 2020 2019 2020 2019
Gross wells 0.0 0.0 1.0 1.0
Net (working interest) wells n/a n/a 1.0 1.0
Success rate, net wells (%)1 n/a n/a 100
%
100
%
  1. For the nine months ended September 30, 2020, the Company drilled one development well with a 100% success rate.

OUTLOOK

The COVID-19 pandemic has resulted in a sharp decline in global economic activity, and consequently, a significant drop in energy demand. There has been a recent resurgence of COVID-19 cases in certain areas and the timing and extent of an eventual economic recovery remains highly uncertain.  

The downturn in oil prices has adversely affected PPR’s operating results and financial position, although the impact has been somewhat muted given that 80% of our 2020 forecast base oil production (net of royalties) is protected by hedges. Our hedging program has shielded the Company against the severe price deterioration that has occurred during these unprecedented times, underpinning the importance of maintaining liquidity and financial position. After completing the Michichi well in March 2020, PPR has suspended our capital program to preserve liquidity and protect development economics. 

Operationally, PPR conducted a bottom-up review of all of our operating expenses and identified and moved forward with immediate reduction opportunities. Operating cost reductions are being realized through rate negotiations, workforce optimizations, shutting-in uneconomic production and the deferral of activities, and are expected to total approximately $2.9 million for the year or $4.0 million on an annualized basis. 

In addition, effective April 2020, executive and non-executive salaries and director annual remuneration were reduced. Certain employee benefit programs have also been suspended. These measures are expected to result in approximately $2.0 million of gross G&A reductions for 2020 or $2.2 million on an annualized basis.

PPR continues to actively monitor and pursue available COVID-19 relief programs and has to date realized some benefit under the Canada Emergency Wage Subsidy and the Site Rehabilitation Program for federal funding of abandonment and reclamation work.

As a result of the ongoing impacts caused by COVID-19, the Company expects the remainder of 2020 and first half of 2021 to be a challenging time for our industry and for the global economy in general. While PPR cannot control or influence the macro environment, we are committed to maintaining our balance sheet and liquidity through active cost reduction efforts and will continue to work closely with our lenders.

ABOUT PRAIRIE PROVIDENT

Prairie Provident is a Calgary-based company engaged in the exploration and development of oil and natural gas properties in Alberta. The Company’s strategy is to grow organically in combination with accretive acquisitions of conventional oil prospects, which can be efficiently developed. Prairie Provident’s operations are primarily focused at the Michichi and Princess areas in Southern Alberta targeting the Banff, the Ellerslie and the Lithic Glauconite formations, along with an established and proven waterflood project at our Evi area in the Peace River Arch. Prairie Provident protects our balance sheet through an active hedging program and manages risk by allocating capital to opportunities offering maximum shareholder returns.

For further information, please contact:

Prairie Provident Resources Inc.

Tim Granger – Chief Executive Officer
Tel: (403) 292-8110
Email: [email protected]

Tony van Winkoop – President
Tel: (403) 292-8071
Email: [email protected]


Forward-Looking Statements

This news release contains certain statements (“forward-looking statements”) that constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future performance, events or circumstances, are based upon internal assumptions, plans, intentions, expectations and beliefs, and are subject to risks and uncertainties that may cause actual results or events to differ materially from those indicated or suggested therein. All statements other than statements of current or historical fact constitute forward-looking statements. Forward-looking statements are typically, but not always, identified by words such as “anticipate”, “believe”, “expect”, “intend”, “plan”, “budget”, “forecast”, “target”, “estimate”, “propose”, “potential”, “project”, “continue”, “may”, “will”, “should” or similar words suggesting future outcomes or events or statements regarding an outlook.

Without limiting the foregoing, this news release contains forward-looking statements pertaining to: the Company’s liquidity and financial position going-forward; cost reduction opportunities (including anticipated amounts) and the Company’s ability to achieve them; and future improvements in economic activity and energy demand.

Forward-looking statements are based on a number of material factors, expectations or assumptions of Prairie Provident which have been used to develop such statements but which may prove to be incorrect. Although the Company believes that the expectations and assumptions reflected in such forward-looking statements are reasonable, undue reliance should not be placed on forward-looking statements, which are inherently uncertain and depend upon the accuracy of such expectations and assumptions. Prairie Provident can give no assurance that the forward-looking statements contained herein will prove to be correct or that the expectations and assumptions upon which they are based will occur or be realized. Actual results or events will differ, and the differences may be material and adverse to the Company. In addition to other factors and assumptions which may be identified herein, assumptions have been made regarding, among other things: future commodity prices and currency exchange rates, including consistency of future prices with current price forecasts; the economic impacts of the COVID-19 pandemic, including the adverse effect on global energy demand, and the oversupply of oil production; results from development activities, and their consistency with past operations; the quality of the reservoirs in which Prairie Provident operates and continued performance from existing wells, including production profile, decline rate and product mix; the accuracy of the estimates of Prairie Provident’s reserves volumes; operating and other costs, including the ability to achieve and maintain cost improvements; continued availability of external financing and cash flow to fund Prairie Provident’s current and future plans and expenditures, with external financing on acceptable terms; the impact of competition; the general stability of the economic and political environment in which Prairie Provident operates; the general continuance of current industry conditions; the timely receipt of any required regulatory approvals; the ability of Prairie Provident to obtain qualified staff, equipment and services in a timely and cost efficient manner; drilling results; the ability of the operator of the projects in which Prairie Provident has an interest in to operate the field in a safe, efficient and effective manner; field production rates and decline rates; the ability to replace and expand oil and natural gas reserves through acquisition, development and exploration; the timing and cost of pipeline, storage and facility construction and expansion and the ability of Prairie Provident to secure adequate product transportation; regulatory framework regarding royalties, taxes and environmental matters in the jurisdictions in which Prairie Provident operates; and the ability of Prairie Provident to successfully market its oil and natural gas products.

Forward-looking statements are not guarantees of future performance or promises of future outcomes, and should not be relied upon. Such statements, including the assumptions made in respect thereof, involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements including, without limitation: changes in realized commodity prices; changes in the demand for or supply of Prairie Provident’s products; the early stage of development of some of the evaluated areas and zones; the potential for variation in the quality of the geologic formations targeted by Prairie Provident’s operations; unanticipated operating results or production declines; changes in tax or environmental laws, royalty rates or other regulatory matters; changes in development plans of Prairie Provident or by third party operators; increased debt levels or debt service requirements; inaccurate estimation of Prairie Provident’s oil and gas reserves volumes; limited, unfavourable or a lack of access to capital markets; increased costs; a lack of adequate insurance coverage; the impact of competitors; and such other risks as may be detailed from time-to-time in Prairie Provident’s public disclosure documents, (including, without limitation, those risks identified in this news release and Prairie Provident’s current Annual Information Form).

The forward-looking statements contained in this news release speak only as of the date of this news release, and Prairie Provident assumes no obligation to publicly update or revise them to reflect new events or circumstances, or otherwise, except as may be required pursuant to applicable laws. All forward-looking statements contained in this news release are expressly qualified by this cautionary statement.


Barrels of Oil Equivalent

The oil and gas industry commonly expresses production volumes and reserves on a “barrel of oil equivalent” basis (“boe”) whereby natural gas volumes are converted at the ratio of six thousand cubic feet to one barrel of oil. The intention is to sum oil and natural gas measurement units into one basis for improved analysis of results and comparisons with other industry participants. A boe conversion ratio of six thousand cubic feet to one barrel of oil is based on an energy equivalency conversion method primarily applicable at the burner tip. It does not represent a value equivalency at the wellhead nor at the plant gate, which is where Prairie Provident sells its production volumes.  Boes may therefore be a misleading measure, particularly if used in isolation. Given that the value ratio based on the current price of crude oil as compared to natural gas is significantly different from the energy equivalency ratio of 6:1, utilizing a 6:1 conversion ratio may be misleading as an indication of value.


Non-IFRS Measures

The Company uses certain terms in this news release and within the MD&A that do not have a standardized or prescribed meaning under International Financial Reporting Standards (IFRS), and, accordingly these measurements may not be comparable with the calculation of similar measurements used by other companies. For a reconciliation of each non-IFRS measure to its nearest IFRS measure, please refer to the “Non-IFRS Measures” section in the MD&A.  Non-IFRS measures are provided as supplementary information by which readers may wish to consider the Company’s performance but should not be relied upon for comparative or investment purposes. The non-IFRS measures used in this news release are summarized as follows:


Working Capital

– Working capital (deficit) is calculated as current assets excluding the current portion of derivative instruments, less accounts payable and accrued liabilities. This measure is used to assist management and investors in understanding liquidity at a specific point in time.  The current portion of derivatives instruments is excluded as management intends to hold derivative contracts through to maturity rather than realizing the value at a point in time through liquidation. The current portion of bank debt is excluded from working capital calculation as it relates to financing activities and is included in net debt calculation. The current portion of decommissioning expenditures is excluded as these costs are discretionary and the current portion of flow-through share premium and warrant liabilities are excluded as it is a non-monetary liability. Lease liabilities have historically been excluded as they were not recorded on the balance sheet until the adoption of IFRS 16 – Leases on January 1, 2019.


Net Debt

– Net debt is defined as bank debt plus working capital surplus or deficit. Net debt is commonly used in the oil and gas industry for assessing the liquidity of a company.


Operating Netback

– Operating netback is a non-IFRS measure commonly used in the oil and gas industry. This measurement assists management and investors to evaluate the specific operating performance at the oil and gas lease level. Operating netbacks included in this news release were determined by taking (oil and gas revenues less royalties less operating costs). Operating netback may be expressed in absolute dollar basis or per unit basis. Per unit amounts are determined by dividing the absolute value by gross working interest production. Operating netback, including realized commodity (loss) and gain, adjusts the operating netback for only realized gains and losses on derivative instruments.


Adjusted Funds Flow

– Adjusted funds flow is calculated based on cash flow from operating activities before changes in non-cash working capital, transaction costs, restructuring costs, and other non-recurring items. Management believes that such a measure provides an insightful assessment of PPR’s operational performance on a continuing basis by eliminating certain non-cash charges and charges that are non-recurring or discretionary and utilizes the measure to assess its ability to finance capital expenditures and debt repayments. Adjusted funds flow as presented is not intended to represent cash flow from operating activities, net earnings or other measures of financial performance calculated in accordance with IFRS. Adjusted funds flow per share is calculated based on the weighted average number of common shares outstanding consistent with the calculation of earnings per share.


Net Capital Expenditures

– Net capital expenditures is a non-IFRS measure commonly used in the oil and gas industry. The measurement assists management and investors to measure PPR’s investment in the Company’s existing asset base. Net capital expenditures is calculated by taking total capital expenditures, which is the sum of property and equipment and exploration and evaluation expenditures from the consolidated statement of cash flows, plus capitalized stock-based compensation, plus acquisitions from business combinations, which is the outflow cash consideration paid to acquire oil and gas properties, less asset dispositions (net of acquisitions), which is the cash proceeds from the disposition of producing properties and undeveloped lands. 

VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress

Positive FDA Meeting Sets Key Pathway for Pivotal PH94B Phase 3 Study in the Second Quarter of 2021

Received Over $17.5 Million Net Proceeds from PH94B Upfront License Payment and Public Offering of Common Stock

Positive New Data from Second Preclinical Study of AV-101 in Combination with Probenecid

Positive Preclinical Data Differentiating Mechanism of Action of PH94B from Risk-Ridden Benzodiazepines

PR Newswire

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ — VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today reported its financial results for the fiscal 2021 second quarter ended September 30, 2020 and provided an update on its CNS pipeline and business progress.

“We see a significant rise in mental health concerns as the global COVID-19 pandemic continues to impact the daily lives of millions of individuals. We are committed to developing innovative therapies that provide relief to those suffering from anxiety and depression, and we are working diligently towards that goal. We are making significant progress in preparing PH94B for launch of a pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder in the second quarter of 2021. After reaching consensus with the FDA on the key components of the study design, it will be very similar to the statistically significant Phase 2 study of PH94B in social anxiety disorder. We are also working with the FDA to finalize details for our Phase 2A study of PH94B in adjustment disorder, which we are planning to initiate in early 2021,” said Shawn Singh, Chief Executive Officer of VistaGen.

“Millions of people rely on benzodiazepines and other prescription drugs to manage symptoms of stress and anxiety. While some medications are safe and effective treatments, many in the current treatment paradigm have limited therapeutic benefits and potentially serious side effects and safety concerns. In Phase 2 clinical studies, PH94B produced rapid onset anti-anxiety effects without requiring systemic uptake and distribution. With its rapid-onset pharmacology, lack of systemic exposure and sedation, and its excellent safety profile in all studies to date, we believe PH94B has the potential to displace benzodiazepines in the drug treatment paradigm for anxiety disorders. In addition to social anxiety disorder, we believe PH94B also has potential as a novel treatment for adjustment disorder, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and other anxiety-related disorders, and we look forward to assessing its potential in various controlled Phase 2 clinical studies in parallel with our Phase 3 program to assess its potential as an acute treatment of anxiety in adults with social anxiety disorder,” concluded Mr. Singh. 

CNS Pipeline Highlights and Updates:

PH94B

  • VistaGen reached consensus with the FDA on key study design and execution aspects of the Company’s initial pivotal Phase 3 study of PH94B for acute treatment of anxiety in adults with social anxiety disorder (SAD):
    • As in the statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, VistaGen’s Phase 3 study will involve a laboratory-simulated anxiety-provoking public speaking challenge.
    • The Phase 3 study will be a randomized, double-blind, placebo-controlled, parallel comparison study conducted at approximately 15 sites in North America.
    • The Subjective Units of Distress Scale (SUDS) will be used to assess the primary efficacy endpoint in the study.
    • Dr. Michael Liebowitz, Professor of Clinical Psychiatry at Columbia University, director of the Medical Research Network in New York City, and creator of the Liebowitz Social Anxiety Scale (LSAS), will be the Principal Investigator of the study.
    • Target enrollment (completed subjects) will be approximately 182 adults with SAD.
    • Study expected to initiate recruitment in 2Q 2021.
  • VistaGen is currently preparing for an exploratory Phase 2A clinical study of PH94B for acute treatment of adjustment disorder (AjD), an emotional or behavioral reaction considered excessive or out of proportion to a stressful event or significant life change, occurring within three months of the stressor, and/or significantly impairing a person’s social, occupational and/or other important areas of functioning. Given the diverse impact of the COVID-19 pandemic, including, among other things, fear and anxiety about health and safety, economic loss, unemployment, social isolation, disruption of established education and work practices, VistaGen submitted its preliminary protocol for the study to the FDA through the FDA’s Coronavirus Treatment Acceleration Program (CTAP). Following that submission, the Company has continued its discussions with the FDA’s Division of Psychiatric Products to determine the study’s appropriate next steps, including the final study protocol.
    • The Company is planning to conduct the proposed Phase 2A study in New York City and enroll approximately 25 to 30 subjects suffering from adjustment disorder-provoking stressors, including, but not limited to, stressors related to the diverse impact of the COVID-19 pandemic and recent civil unrest in the U.S.
    • The AjD study is expected to initiate patient recruitment in 1Q 2021.
    • The Company is also planning for additional exploratory Phase 2A studies in postpartum anxiety, post-traumatic stress disorder, and pre-procedural anxiety (pre-MRI).
  • VistaGen reported new in vitro electrophysiology data demonstrating that the mechanism of action of PH94B, does not involve direct activation of GABA-A receptors, in distinct contrast to the mechanism of action of benzodiazepines, which act as direct positive modulators of GABA-A receptors.
    • These studies are significant because they indicate that PH94B has no relevant benzodiazepine-like activity, confirming PH94B’s potential to produce rapid-onset benzo-like, anti-anxiety effects, without the risky side effects and safety concerns of benzos.

AV-101                  

  • VistaGen reported positive new data from the Company’s second preclinical study of its oral investigational drug, AV-101, combined with probenecid, an FDA-approved drug for treatment of gout used adjunctively to increase the therapeutic benefit of numerous antibacterial, anticancer and antiviral drugs.
    • The results of this new study complement previous preclinical data demonstrating the combination’s potential to substantially increase the brain concentration of AV-101’s active metabolite, 7-Cl-KYN, a potent and selective full antagonist of the NMDA receptor glycine co-agonist site, thereby reducing, rather than blocking, NMDA receptor signaling.

Partnering Activity

  • VistaGen received a $5 million non-dilutive upfront license payment from EverInsight Therapeutics (now AffaMed Therapeutics), the Company’s strategic partner for Phase 3 development and commercialization of PH94B for anxiety-related disorders in key markets in Asia.
  • Upon successful development and commercialization of PH94B in the licensed territory, VistaGen is eligible to receive up to $172 million in additional development and commercial milestone payments, plus royalties on commercial sales of PH94B.

Capital Resources

  • VistaGen completed an underwritten public offering of common stock resulting in gross proceeds of $14.29 million to the Company, before underwriting discounts and commissions and offering expenses.

Financial Results for the Fiscal Quarter Ended September 30, 2020:

Net loss: Net loss attributable to common stockholders for the fiscal quarter ended September 30, 2020 decreased to approximately $3.7 million compared to $5.7 million for the fiscal quarter ended September 30, 2019. For the six-month period ending September 30, 2020, the net loss attributable to common stockholders was approximately $7.1 million, a decrease from approximately $12.2 million reported in the same period last year.

Revenue: Total revenue for the fiscal quarter ended September 30, 2020 was $334,000, representing the revenue recognition related to its agreement with EverInsight Therapeutics (now AffaMed Therapeutics), pursuant to which the Company received a non-dilutive upfront license fee payment of $5.0 million on August 3, 2020. VistaGen recognized $334,000 in sublicense revenue pursuant to this agreement in the six months ended September 30, 2020 compared to no revenue in the six months ended September 30, 2019. The Company expects to continue recognizing revenue pursuant to this payment in future periods during our fiscal year ending March 31, 2021 and thereafter.

Research and development (R&D) expense:  Research and development expense decreased from $4.2 million in the quarter ended September 30, 2019 to $2.4 million for the quarter ended September 30, 2020. Research and development expense also decreased from $8.5 million to $4.1 million for the six months ended September 30, 2019 and 2020, respectively, in both cases, primarily due to the completion of the Company’s Phase 2 study of AV-101 as a potential adjunctive treatment of major depressive disorder in the fourth calendar quarter of 2019. Expenses related to that study and other nonclinical activities related to AV-101 decreased by $4.8 million for the six months ended September 30, 2020 compared to similar expense in the six months ended September 30, 2019. Noncash research and development expenses, primarily stock-based compensation and depreciation in both periods, accounted for approximately $391,000 and $607,000 in the six months ended September 30, 2020 and 2019, respectively.

General and administrative (G&A) expense: General and administrative expense totaled $1.3 million for the three months ended September 30, 2020 as compared to $1.2 million for the same period in the year prior. General and administrative expense decreased to approximately $2.7 million from approximately $3.1 million for the six months ended September 30, 2020 and 2019, respectively. Noncash general and administrative expense, $804,000 in the six months ended September 30, 2020, decreased from $1,044,000 in the six months ended September 30, 2019 primarily due to decreases in stock-based compensation and the noncash components of investor and public relations expense attributable to the amortization of the fair value of equity securities granted to service providers.

Cash Position: At September 30, 2020, the Company had cash and cash equivalents of approximately $15.4 million. During the quarter ended September 30, 2020, the Company received net proceeds totaling approximately $17.5 million from (i) the $5.0 million gross non-dilutive upfront license fee payment from EverInsight Therapeutics (now AffaMed Therapeutics), and (ii) the gross proceeds of approximately $14.29 million from the sale of shares of its common stock in an underwritten public offering.

As of November 12, 2020, the Company had 73,998,057 shares of common stock outstanding.

About VistaGen
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.

Forward Looking Statements

Various statements in this release are “forward-looking statements” concerning VistaGen’s future expectations, plans and prospects. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: successful development, including, but not limited to Phase 3 development, and approval of one or more of the Company’s drug candidates may not be achieved in any market for any indication, and, if approved, may not be differentiated from the standard of care; the FDA and other regulatory authorities may decide that the results of one or more of the Company’s development programs are not sufficient for regulatory approval; development of the Company’s drug candidates may not be successful in any indication; success in nonclinical studies or in earlier-stage clinical studies may not be repeated or observed in future studies; and other adverse events or market conditions may be encountered, at any stage of development, that negatively impact further development, including entry of competitive products or other technical and unexpected hurdles in the development, manufacture and commercialization of the Company’s drug candidates. Additional risks are more fully discussed in the section entitled “Risk Factors” in VistaGen’s most recent Annual Report on Form 10-K for the year ended March 31, 2020, and in its subsequent quarterly reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. Any forward-looking statements represent the Company’s views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements.


VISTAGEN THERAPEUTICS, INC.


CONSOLIDATED BALANCE SHEETS

(Amounts in dollars, except share amounts)


September 30,


 March 31, 


2020


2020


 (Unaudited)


(Note 1)


 ASSETS 

 Current assets: 

 Cash and cash equivalents  

$        15,399,500

$          1,355,100

 Prepaid expenses and other current assets 

455,700

225,100

    Deferred contract acquisition costs – current portion 

116,900

 Total current assets  

15,972,100

1,580,200

 Property and equipment, net  

257,600

209,600

 Right of use asset – operating lease 

3,403,000

3,579,600

 Deferred offering costs 

268,500

355,100

 Deferred contract acquisition cost – non-current portion 

321,700

 Security deposits and other assets  

47,800

47,800

 Total assets  

$        20,270,700

$          5,772,300


 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) 

 Current liabilities: 

 Accounts payable  

$          1,176,400

$          1,836,600

 Accrued expenses  

186,900

561,500

 Current notes payable, including accrued interest 

352,600

56,500

 Deferred revenue – current portion 

1,244,000

 Operating lease obligation – current portion 

338,500

313,400

 Financing lease obligation – current portion  

3,500

3,300

 Total current liabilities  

3,301,900

2,771,300

 Non-current liabilities: 

 Non-current portion of notes payable 

87,300

 Accrued dividends on Series B Preferred Stock 

5,694,700

5,011,800

 Deferred revenue – non-current portion 

3,422,000

 Operating lease obligation – non-current portion 

3,540,900

3,715,600

 Financing lease obligation – non-current portion  

1,300

3,000

 Total non-current liabilities  

12,746,200

8,730,400

 Total liabilities  

16,048,100

11,501,700

 Commitments and contingencies 

 Stockholders’ equity (deficit): 

      Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2020 and March 31, 2020: 

          Series A Preferred, 500,000 shares authorized, issued and outstanding at September 30, 2020 and March 31, 2020 

500

500

             Series B Preferred; 4,000,000 shares authorized at September 30, 2020 and March 31, 2020; 1,160,240 shares issued and outstanding at September 30, 2020 and March 31, 2020 

1,200

1,200

            Series C Preferred; 3,000,000 shares authorized at September 30, 2020 and March 31, 2020; 2,318,012 shares issued and outstanding at September 30, 2020 and March 31, 2020 

2,300

2,300

        Common stock, $0.001 par value; 175,000,000 shares authorized at September 30, 2020 and March 31, 2020; 74,133,722 and 49,348,707 shares issued and outstanding at September 30, 2020 and March 31, 2020, respectively

74,100

49,300

 Additional paid-in capital  

216,444,600

200,092,800

 Treasury stock, at cost, 135,665 shares of common stock held at September 30, 2020 and March 31, 2020 

(3,968,100)

(3,968,100)

 Accumulated deficit 

(208,332,000)

(201,907,400)

 Total stockholders’ equity (deficit) 

4,222,600

(5,729,400)

 Total liabilities and stockholders’ equity (deficit) 

$        20,270,700

$          5,772,300

Note 1:  Derived from audited Consolidated Balance Sheet at March 31, 2020

 


VISTAGEN THERAPEUTICS


CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Amounts in Dollars, except share amounts)

(Unaudited)


 Three Months Ended September 30,  


 Six Months Ended September 30, 


2020


2019


2020


2019

 Sublicense revenue

$               334,000

$                         –

$               334,000

$                          –

  Total revenues 

334,000

334,000

Operating expenses:

 Research and development 

2,358,200

4,205,200

4,089,400

8,519,100

 General and administrative 

1,269,500

1,146,100

2,660,100

3,056,200

  Total operating expenses 

3,627,700

5,351,300

6,749,500

11,575,300

Loss from operations 

(3,293,700)

(5,351,300)

(6,415,500)

(11,575,300)

Other income (expenses), net:

 Interest income (expense), net 

(3,900)

15,400

(7,100)

31,900

 Other income

600

Loss before income taxes

(3,297,600)

(5,335,900)

(6,422,000)

(11,543,400)

Income taxes

(200)

(2,600)

(2,400)

Net loss and comprehensive loss

$           (3,297,800)

$           (5,335,900)

$           (6,424,600)

$         (11,545,800)

   Accrued dividends on Series B Preferred stock

(347,200)

(313,800)

(683,000)

(616,300)

Net loss attributable to common stockholders

$           (3,645,000)

$           (5,649,700)

$           (7,107,600)

$         (12,162,100)

Basic and diluted net loss attributable to common stockholders per common share

$                    (0.05)

$                    (0.13)

$                    (0.12)

$                    (0.29)

Weighted average shares used in computing basic and diluted net loss attributable to common stockholders per common share

67,082,935

42,622,965

59,245,209

42,622,965

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/vistagen-therapeutics-reports-fiscal-2021-second-quarter-financial-results-and-provides-highlights-on-its-cns-pipeline-and-business-progress-301172428.html

SOURCE VistaGen Therapeutics